Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus

JAMA Dermatology

Volumn 150, Issue 3, 2014, Pages 291-296

  Wieczorek, Isabela T ^a,b   Propert, Kathleen J ^b   Okawa, Joyce ^a,b   Werth, Victoria P ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CORTICOSTEROID; DAPSONE; DOUBLE STRANDED DNA ANTIBODY; LUPUS ANTICOAGULANT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; SM ANTIBODY; THALIDOMIDE;

ADULT; ANTIBODY TITER; ARTICLE; CLE DISEASEACTIVITY AND SEVERITY INDEX; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISCOID RASH; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; KIDNEY DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALAR RASH; MALE; MOUTH ULCER; MUCOCUTANEOUS AMERICAN COLLEGE OF RHEUMATOLOGY CRITERIA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PATIENT IDENTIFICATION; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; SKIN LUPUS ERYTHEMATOSUS; SLEDAI; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGE FACTORS; AGED; BIOPSY, NEEDLE; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 84896087559     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.9026     Document Type: Article

References (14)

1. Costner MI, Sontheimer RD. Lupus erythematosus. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest B, Paller AS, Leffell DJ, eds. Fitzpatrick's Dermatology in General Medicine. 7th ed. New York, NY: McGraw-Hill; 2007:chap 156.
2. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271-1277. (Pubitemid 13221242)
3. Grönhagen CM, Gunnarsson I, Svenungsson E, Nyberg F. Cutaneous manifestations and serological findings in 260 patients with systemic lupus erythematosus. Lupus. 2010;19(10):1187-1194.
4. Durosaro O, Davis MD, Reed KB, Rohlinger AL. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol. 2009;145(3):249-253.
5. Grönhagen CM, Fored CM, Granath F, Nyberg F. Cutaneous lupus erythematosus and the association with systemic lupus erythematosus: a population-based cohort of 1088 patients in Sweden. Br J Dermatol. 2011;164(6):1335-1341.
6. López-Longo FJ, Monteagudo I, González CM, Grau R, Carreño L. Systemic lupus erythematosus: clinical expression and anti-Ro/SS - a response in patients with and without lesions of subacute cutaneous lupus erythematosus. Lupus. 1997;6(1):32-39. (Pubitemid 27055733)
7. Black DR, Hornung CA, Schneider PD, Callen JP. Frequency and severity of systemic disease in patients with subacute cutaneous lupus erythematosus. Arch Dermatol. 2002;138(9):1175-1178. (Pubitemid 35025690)
8. Moghadam-Kia S, Chilek K, Gaines E, et al. Cross-sectional analysis of a collaborative web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. Arch Dermatol. 2009;145(3):255-260.
9. Ward MM, Marx AS, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol. 2000;27(3):664-670. (Pubitemid 30151343)
10. Klein R, Moghadam-Kia S, LoMonico J, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol. 2011;147(2):203-208.
11. Klein RS, Morganroth PA, Werth VP. Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument. Rheum Dis Clin North Am. 2010;36(1):33-51.
12. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004: Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005;44(7):902-906. (Pubitemid 41511186)
13. Yee CS, Farewell V, Isenberg DA, et al. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 2007;56(12):4113-4119. (Pubitemid 350262339)
14. Yee CS, Cresswell L, Farewell V, et al. Numerical scoring for the BILAG-2004 index. Rheumatology (Oxford). 2010;49(9):1665-1669.